A61P 35/04
Specific for metastasis
Official title: specific for metastasis
A61P35/04 (Specific for metastasis) appears on 9,096 US grants and 15,402 published applications in this corpus.
Search patents in A61P- Granted patents
- 9,096
- Published applications
- 15,402
- Assignees
- 4,329
- Inventors
- 25,135
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 2 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 2 | 0 |
| 1995 | 5 | 0 |
| 1996 | 14 | 0 |
| 1997 | 25 | 0 |
| 1998 | 31 | 0 |
| 1999 | 48 | 0 |
| 2000 | 79 | 0 |
| 2001 | 104 | 40 |
| 2002 | 159 | 219 |
| 2003 | 149 | 414 |
| 2004 | 142 | 507 |
| 2005 | 124 | 481 |
| 2006 | 199 | 496 |
| 2007 | 187 | 550 |
| 2008 | 276 | 832 |
| 2009 | 331 | 870 |
| 2010 | 511 | 1121 |
| 2011 | 509 | 935 |
| 2012 | 606 | 882 |
| 2013 | 674 | 739 |
| 2014 | 614 | 739 |
| 2015 | 548 | 598 |
| 2016 | 489 | 643 |
| 2017 | 453 | 619 |
| 2018 | 395 | 622 |
| 2019 | 427 | 652 |
| 2020 | 380 | 625 |
| 2021 | 358 | 639 |
| 2022 | 344 | 511 |
| 2023 | 271 | 507 |
| 2024 | 264 | 489 |
| 2025 | 227 | 365 |
| 2026 | 145 | 307 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Anticancer compositions29 Sep 2026US 12,746,230 B2Aragon Pharmaceuticals, Inc.
- Compositions and methods comprising endothelin a receptor antagonists and androgen therapies29 Sep 2026US 12,746,239 B2The United States Government as represented by the Department of Veterans Affairs
- Method of treatment of cancer or tumour29 Sep 2026US 12,746,272 B2
- Histone deacetylase inhibitors for use in immunotherapy22 Sep 2026US 12,740,986 B2Viracta Subsidiary, Inc.
- Piperidine urea derivatives for cancer therapy15 Sep 2026US 12,734,164 B2NeuroPn Therapeutics, Inc.
- Liposome compositions and medical uses thereof8 Oct 2026US 2026/0306404 A1
- Egfr inhibitor for treating cancers comprising atypical egfr mutations8 Oct 2026US 2026/0306491 A1Oric Pharmaceuticals, Inc.
- Technologies targeting cell states8 Oct 2026US 2026/0306640 A1Auron Therapeutics, Inc.
- Methods for treating patients with locally advanced or metastatic urothelial cancer with antibody drug conjugates (adc) that bind 191p4d12 proteins in combination with pembrolizumab8 Oct 2026US 2026/0306649 A1Agensys, Inc.
- Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof8 Oct 2026US 2026/0308155 A1BeOne Medicines I GmbH
Most cited
By later US patents
- Method of treating androgen independent prostate cancer1,091US 9,040,574 B2Natrogen Therapeutics International, Inc. · 2015
- Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation733US 9,101,621 B2Celgene Corporation · 2015
- Human antibodies that bind human TNF.alpha.451US 6,090,382 ABASF SE · 2000
- Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1328US 7,595,048 B2Ono Pharmaceutical Co., Ltd. · 2009
- Human antibodies that bind human TNFα308US 6,258,562 B1BASF SE · 2001